The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS). Read more
FDA approves Susvimo continuous drug delivery implant for AMD
The US Food and Drug Administration (FDA) has approved the Susvimo implant which delivers ranibizumab continuously, offering patients living with neovascular age-related macular degeneration (nAMD) an alternative to more frequent anti-VEGF eye injections. Read more
Prof Robyn Guymer ‘thrilled’ by Phase 3 results of pegcetacoplan for dry AMD
Prominent Melbourne retinal disease researcher Professor Robyn Guymer is encouraged by the Phase 3 results of a trial she’s been involved in, investigating a new therapy she says is the only intervention shown to significantly slow the growth of lesions in dry AMD. Read more
Infrared light could replace injections for macular oedema
A clinical trial at Sydney Eye Hospital is evaluating the safety and efficacy of using infrared light to treat macular oedema from retinal vein occlusions, instead of the current standard treatment of eye injections. Read more
MDFA awards $1 million in research grants to eight projects
Eight Australian researchers are taking their projects to the next level with a share of more than $1 million in research funding from Macular Disease Foundation Australia (MDFA). Read more
New frontiers in treating late-stage AMD
As part of Macula Month this May, Insight examines drug development programs that could significantly alter the late-stage AMD therapy landscape. Leading experts also discuss why optometrists are such an important link in the success of both patient outcomes and clinical trials.
Gene therapy trial for dry AMD under way in Australia
Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre for Eye Research Australia (CERA). Read more
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment. Read more
Shifting the dial on diabetes-related blindness
Two years since the KeepSight launch, Insight asks what measurable difference this once-in-a-generation program is making to those living with the diabetes.
New WA children’s clinic to revolutionise diabetic eye treatment
A new diabetic eye clinic for children in Western Australia, which opened last month, is part of the Lions Eye Institute’s first major clinical-research platform for children’s eye health.
Read more